Excitement over immunomodulation inundates clinical research meetings.
Goldsmith
M F
MF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000628:therapy; D001804:Blood Transfusion, Autologous; D004167:Diphtheria Toxin / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion; D009369:Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011993:Recombinant Fusion Proteins; D012772:Shock, Septic / Q000628:therapy
D000911:Antibodies, Monoclonal; C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins